{"pub": "reuters", "url": "https://reuters.com/article/us-biotoscana-inves-m-a/latin-american-pharma-biotoscana-confirms-in-sale-talks-filing-idUSKBN1WN1JW", "downloaded_at": "2019-10-08 15:18:01.755781+00:00", "title": "Latin American pharma Biotoscana confirms in sale talks: filing", "language": "en", "text": "SAO PAULO (Reuters) - Latin American pharmaceutical company Biotoscana Investments (GBIO33.SA) confirmed that its shareholders were in talks with investors about a sale, according to a securities filing on Monday.\n\n\u201cThe company\u2019s shareholders are in talks with investors, but have not yet taken a decision on a transaction\u201d, it said, adding there would be a mandatory offering to all shareholders if the company\u2019s control changed.\n\nReuters reported on Monday that Brazilian pharmaceutical firm Eurofarma and Canada\u2019s Knight Therapeutics (GUD.TO) were in talks with Biotoscana\u2019s shareholders, led by private equity fund Advent International.", "description": "Latin American pharmaceutical company Biotoscana Investments confirmed that its shareholders were in talks with investors about a sale, according to a securities filing on Monday.", "authors": ["Reuters Editorial", "Min Read"], "top_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "published_at": "2019-10-08"}